AI-generated research brief — verify at source
Low-Dose Olanzapine Significantly Improves Nausea Control With Moderately Emetogenic Chemotherapy
In a randomized, double-blind trial of 139 patients receiving moderately emetogenic chemotherapy, adding 5 mg olanzapine to ondansetron and dexamethasone significantly improved total control of nausea and vomiting compared with placebo (62.3% vs. 38.6%, p = 0.005). The primary endpoint of total protection showed a meaningful but statistically non-significant trend in favor of olanzapine (71.0% vs. 55.7%, p = 0.06), suggesting a real benefit that the trial may have been underpowered to confirm definitively.
What Was Studied
This trial investigated whether adding low-dose olanzapine (5 mg) to a standard two-drug antiemetic backbone of ondansetron and dexamethasone could improve prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based regimens. This question is clinically relevant because these moderately emetogenic regimens remain a common source of patient distress, and current guideline-recommended three-drug approaches typically incorporate NK1 receptor antagonists, which may be costly or less accessible than olanzapine.
How It Was Studied
This was a randomized, double-blind, placebo-controlled trial enrolling patients initiating one of three moderately emetogenic chemotherapy regimens. Participants were allocated 1:1 to receive either olanzapine 5 mg or matched placebo on days 1 through 4, alongside ondansetron and dexamethasone in both arms. Randomization was stratified by chemotherapy type and by the presence of high-risk features for CINV, specifically female patients under age 50. The primary assessment window extended to 120 hours post-chemotherapy, and 139 patients were evaluable for the primary endpoint analysis.
What Was Observed
- Total control — defined as complete absence of vomiting, no use of rescue medication, and no more than mild nausea — was achieved by significantly more patients in the olanzapine group than in the placebo group (62.3% vs. 38.6%, p = 0.005), representing a roughly 24 percentage-point absolute difference that is clinically meaningful.
- Total protection — the primary endpoint, which additionally required no nausea beyond mild — was achieved in 71.0% of olanzapine-treated patients versus 55.7% of placebo recipients. This 15-percentage-point difference did not reach conventional statistical significance (p = 0.06), leaving the primary endpoint technically unmet, though the trend was consistent and clinically noteworthy.
- Delayed nausea of grade 2 or higher, occurring beyond the acute phase, was substantially less common with olanzapine (13.0% vs. 30.0%, p = 0.015), indicating that the drug’s benefit was particularly pronounced in the delayed CINV window where control is traditionally more difficult to achieve.
- Patient preference strongly favored the olanzapine regimen: 95.6% of patients in that arm wished to continue the same antiemetic regimen in future cycles, compared with 72.9% of placebo recipients (p = 0.001). Somnolence rates were comparable between arms, and anorexia appeared less frequent with olanzapine.
Why This Matters
These findings contribute to a growing body of evidence supporting olanzapine’s role in CINV prophylaxis, extending its potential utility from highly emetogenic chemotherapy into moderately emetogenic regimens. The significant improvement in total control and delayed nausea specifically is important, as the delayed phase has historically been the most challenging to manage. If confirmed in larger trials, low-dose olanzapine could represent an affordable and effective alternative to NK1 receptor antagonists in the moderately emetogenic setting.
How to Read This Result
With only 139 evaluable patients and a primary endpoint that narrowly missed statistical significance, this trial should be interpreted as generating a strong hypothesis rather than providing definitive confirmation of olanzapine’s superiority in this setting.
Limitations
The abstract does not explicitly report study limitations.